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Individualized Treatment 
of Squamous Cell Carcinoma 
of the Anus
Luc Dewit, Annemieke Cats and Geerard Beets
Abstract
Treatment of squamous cell carcinoma of the anus has evolved over the last 
5 decades from radical surgery to combined chemoradiation therapy. Radiation 
treatment techniques have dramatically improved with the development of more 
powerful computers, algorithms and treatment machines. The clinical impact of the 
modern radiation treatment techniques, such as intensity-modulated radiotherapy 
and volumetric modulated arc therapy, is discussed. The standard-of-care regi-
men still is concurrent Mitomycin C, 5-fluorouracil and high-dose radiation, as 
was conceived 45 years ago. Variants of this schedule are discussed in this chapter. 
International guidelines have been generated and implemented. Whereas concur-
rent chemoradiation therapy is the treatment of choice for locally advanced tumors, 
early tumors are probably adequately controlled with either reduced dose chemo-
radiation therapy or radiation therapy alone. Prognostic factors, such as high-risk 
human papillomavirus, epidermal growth factor receptor and immune response, 
will be highlighted. The role of surgery in primary care is limited to local excision 
of T1N0 tumors ≤ 1 cm of the anal margin. Salvage radical surgery is limited to 
locoregional recurrent, non-metastasized and resectable tumors after chemoradia-
tion therapy. In addition, new treatment modalities, such as targeted therapy and 
immunotherapy, will be discussed. Current research aims at refining prognostic 
subgroups to further individualize treatment strategy, implementing quality 
assurance protocols in international trials and investigating the molecular profile of 
squamous cell carcinoma of the anus, in order to identify new treatment avenues. 
This will hopefully change the landscape of anal cancer treatment in the future.
Keywords: anal carcinoma, radiotherapy, chemoradiation therapy,  
prognostic factors, surgery, biological agents
1. Introduction
Squamous cell carcinoma of the anus (SCCA) is a rare tumor with an increasing 
incidence over the last decades [1]. It originates from the basal cells of the epithelial 
“If you do not change direction, you may end up where you are heading”,
Lao Tsu, Chinese philosopher.
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layer of the anal canal, which extends from the anorectal junction to the anal ori-
fice, or anal margin, which extends from the anal orifice to a radius of 5 cm laterally 
[2]. Tumors arising from the anal margin have a different biological behavior, and 
this will be briefly discussed later in this chapter. Most, but not all, SCCA are caus-
ally related with high-risk human papillomavirus (HPV-HR), mainly subtypes 16 
and 18 [3, 4]. These tumors develop from high grade anal intraepithelial neoplasia 
(AIN3) through a number of consecutive oncogenic steps, which are only partially 
understood [5]. Radical surgery, which usually implies an abdominoperineal resec-
tion with a permanent end colostomy, has been shown to yield 5-year survival rates 
of only 20–70%, depending on stage and resection margins [6]. Radiation therapy 
has demonstrated superior survival rates with a high probability of organ preserva-
tion. The seminal papers of Nigro and colleagues have shown that the combination 
of radiation and chemotherapy resulted in even better survival rates, at least for 
locally advanced cases [7, 8]. This has been confirmed in two landmark randomized 
phase III trials [9, 10]. Hence, chemoradiation therapy (CRT) has largely replaced 
radical surgery in the treatment of SCCA.
The focus of this chapter is to highlight the evolving concepts toward indi-
vidualized treatment of patients with SCCA, based upon prognostic parameters. 
Emphasis will be given to improved radiation treatment techniques, concurrent and 
(neo) adjuvant chemotherapy regimens, the role of HPV status, molecular markers 
and immune response. In addition, the role of surgery will be addressed.
2. Improved treatment of SCCA
2.1 Technical improvement of radiation treatment of SCCA
2.1.1 Radiation dose and target volume
The efficacy of (chemo)radiation treatment for SCCA has been known for 
several decades. The acute and late toxicity, however, was considerable with the 
large, non-conformal treatment fields, which often resulted in moderate functional 
outcome and quality of life [11]. With the development of more powerful comput-
ers, algorithms and treatment machines, more sophisticated treatment techniques 
became available. This has resulted in a shift from standard opposed anterior-
posterior fields (AP-PA) or a four-field technique in the fifties through eighties of 
the previous century to 3D-conformal radiotherapy (3D-CRT) in the nineties and 
intensity-modulated radiotherapy (IMRT) in the early years of this century and 
volumetric modulated arc therapy (VMAT) in the last decade.
The difference in toxicity between 3D-CRT and IMRT or VMAT has never been 
compared in a prospective randomized trial, but several retrospective studies and one 
recent prospective study have reported an improved toxicity profile with the newer 
techniques [12–17]. A recent national audit in the UK comparing these techniques con-
firmed the reduced toxicity with IMRT (Table 1) [18]. A few studies also claim a better 
disease-free survival (DFS) and locoregional control (LRC) with IMRT [12, 14, 19].
Toxicity is largely related to the radiation dose and the volume of normal tissues 
exposed to radiation, which in turn is related to the gross tumor volume (GTV) 
and clinical and planning target volume (CTV and PTV). The GTV is determined 
by the macroscopic local tumor extent and documented macroscopically involved 
regional lymph nodes, whereas the CTV is dependent on the site of regional lymph 
nodes that are considered to be at risk for microscopic metastatic disease. In addi-
tion, the PTV is determined by the set-up error of patient positioning. With the 
advent of magnetic resonance imaging (MRI) and fluor-18-deoxyglucose positron 
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emission tomography (18F FDG-PET), much improvement is made over the years 
in visualizing the primary tumor and involved regional lymph nodes and, hence, 
delineating GTV. In contrast, the estimation of microscopic metastatic disease 
remains poor and is largely based upon a few studies with documented locoregional 
recurrence in relation to tumor size and irradiated volumes [20–22]. The CTV for 
SCCA is notoriously complex, given the potential involvement of inguinal, iliac, 
mesorectal and presacral lymph nodes. Consensus contouring guidelines have been 
developed to assist radiation oncologists in setting up a treatment plan [23, 24]. 
With respect to the radiation dose, a two or three dose level for microscopic and 
macroscopic disease has emerged form clinical trials. For instance, in the Radiation 
Therapy Oncology Group (RTOG) 87-11 trial, a radiation dose of 30.6 Gy was given 
to the common iliac lymph nodes whereas a dose of 45 Gy was delivered to the 
lower iliac lymph nodes and 50.4 Gy to the primary tumor [25]. In contrast, in the 
United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial 
(UKCCCR-ACT) I and the European Organization For Research and Treatment of 
Cancer Radiotherapy (EORTC) 22861 trial the common iliac lymph nodes were not 
included in the elective radiation field, whereas a dose of 45 Gy was given to the 
lower iliac and inguinal lymph nodes with a boost to 60–65 Gy to the primary tumor 
[9, 10]. In the subsequent UKCCCR-ACT II the dose to the iliac and inguinal lymph 
nodes was limited to 30.6 Gy and the boost to the primary tumor to 50.4 Gy [26]. 
Despite these differences in radiation dose and volume, no striking difference in 
LRC was observed between these trials [9, 10, 25]. A number of retrospective stud-
ies have reported a better LRC with a higher radiation dose, at least in the locally 
advanced tumors [27–30]. This was confirmed in a systematic literature review 
[31] and a recent retrospective study from a large Scandinavian database [32]. 
However, in the French prospective randomized ACCORD-03 trial, which included 
only locally advanced cases, a marginal, non-significant increase in colostomy-free 
survival (CFS), a surrogate endpoint for LRC, was observed after 70 Gy, as com-
pared with 60 Gy [33]. Consequently, in the absence of definitive evidence, current 
clinical guidelines do not advocate a higher radiation dose for larger tumors [34, 35].
Table 1. 
UK National Audit of anal cancer radiotherapy 2015 [18]. Reproduced with permission of Elsevier.
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2.1.2 The treatment gap
In the initial trials, a treatment gap of 6 weeks was included at an intermediate radi-
ation dose [9, 10, 25]. This was done to allow for recovery from acute radiation toxicity, 
but also to give the tumor time to regress and to assess whether a radiation boost should 
be given with external beam irradiation or with brachytherapy. As results matured and 
further insight in tumor radiobiology was gained, this long treatment gap was consid-
ered to be potentially hazardous, due to the likelihood of tumor repopulation during 
the treatment gap. In the subsequent studies, the treatment gap was shortened to 
2 weeks, which not only seemed to be feasible, but also resulted in better LRC in some 
studies [36–40] but not in others [41, 42]. With the advent of IMRT and VMAT, the 
entire radiation course could be administered without a treatment break. Today, most 
modern radiotherapy centers have implemented IMRT or VMAT for SSCA.
2.2 Chemotherapy and radiation for SCCA
2.2.1 Landmark studies
In June 1973, Dr. Nigro presented 3 cases with SCCA at a meeting of the 
American Proctologic Society in Detroit, that were treated with radiation therapy 
(RT) and concurrent Mitomycin C (MMC) and 5-fluorouracyl (5-FU) in a pre-
operative setting [7]. The rationale for this approach was to improve the LRC and 
overall survival (OS) of SSCA, since the results with radical surgery alone were 
modest, at best. Dr. Nigro realized that, in contrast with rectal cancer, SCCA 
originates from an organ which has an abundant lymphatic vessel supply, that 
allows rapid lymphatic tumor spread. In addition, there is limited space in the 
lower pelvis for radical surgery. The radiation dose was 30 Gy in 3–5 weeks via two 
large anterior-posterior opposed fields, and 30 mg of MMC was given on day 1 in 
a single bolus infusion and 1500 mg per day of 5-FU on days 2–6 in a continuous 
infusion. Six to 8 weeks later, two of them underwent an abdominoperineal resec-
tion, as planned. No tumor was found on microscopic examination of the operation 
specimen in these two cases. The third patient refused surgery and remained free 
of disease 1 year later [7]. This treatment regimen was expanded in a larger series, 
which confirmed the excellent results [43]. This pioneering work formed the basis 
for definitive CRT with higher, therapeutic radiation doses.
The superiority of this regimen compared with RT alone was established in two 
randomized phase III trials, the UKCCCR-ACT I and the EORTC 22861 [9, 10]. 
These trials were executed almost parallel in time and their design was strikingly 
similar, except for the eligibility criteria: in the EORTC trial only locally advanced 
patients were eligible, whereas in the ACT I all stages were accepted for inclusion. 
Despite this imbalance in patient selection, no major difference in the treatment 
outcome was observed between these two trials. Both studies showed a significant 
improvement in LRC control with CRT as compared with RT alone [9, 10]. In the 
ACT I, 3-year LRC increased from 47% after RT alone to 70% after CRT with con-
current 5-FU and MMC [9]. The corresponding figures in the EORTC 22861 trial 
were 55 and 68%, respectively [10]. The difference in LRC and progression-free 
survival (PFS) in the ACT I remained up to 12 years after treatment [44]. However, 
no difference in OS was found in either of these trials [10, 44].
The value of MMC, in addition to 5-FU, was established in the phase III RTOG 
87-04 study [25]. In this trial, however, MMC was given twice in the first and fifth 
week of the radiation treatment, as opposed to only once in the ACT I and EORTC 
22861 trial. It resulted in considerably more grade 4-5 hematological toxicity than 
was seen in the European trials.
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2.2.2 Subsequent pivotal studies
In the subsequent phase III RTOG 98-11 trial, the role of neo-adjuvant and 
concurrent cisplatin and 5-FU was addressed by comparing it with concurrent MMC 
and 5-FU [45]. While the combination of cisplatin and 5-FU was less toxic than 
MMC and 5-FU, the disease-free survival (DFS) and OS was significantly worse 
with the new regimen [46]. In the UKCCCR-ACT II, concurrent cisplatin, 5-FU and 
RT was compared with concurrent MMC, 5-FU and RT, with or without adjuvant 
cisplatin and 5-FU, in a 2 × 2 factorial design [26]. In this trial, which is the largest 
phase III trial carried out to date for anal cancer, no difference in PFS (Figure 1) and 
toxicity was observed between the four treatment arms [26]. The French phase III 
ACCORD 03 trial investigated the value of neo-adjuvant and concurrent cisplatin, 
5-FU and RT, and radiation dose intensification, also in a 2 × 2 factorial design [33]. 
Whereas a marginal, non-significant increase in CFS was observed in the group 
that received the higher radiation dose, no difference in CFS was found between the 
patients with and without neo-adjuvant chemotherapy. Acute and late toxicity were 
similar between the four groups [33]. The EORTC 22011-40014 randomized phase 
II trial compared concurrent MMC, cisplatin and RT with MMC, 5-FU and RT [47]. 
The new combination proved to be highly effective, but more toxic, with a compli-
ance of only 49% as opposed to 79% for the standard arm [47].
2.2.3 Variant schedules
In the UKCCCR-ACT I, EORTC 22861 and RTOG 87-04 trials, MMC was given 
once on day 1 [9, 10] or twice on day 1 and 29 of the radiation treatment [25], 
Figure 1. 
MMC or cisplatin+5FU and radiation + or—adjuvant cisplatin/5-FU for SSCAC [26]. Reproduced with 
permission of Elsevier.
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whereas 5-FU was administered in a continuous infusion day 1–4 or 5 and day 
29–32 or 33. Variants of this treatment schedule have been explored with 5-FU given 
continuously in lower daily doses over the entire split-course radiation treatment 
[37], or by replacing 5-FU with capecitabine, an oral prodrug of 5-FU, given twice 
daily during the radiation treatment [48–51]. These schedules seemed feasible and 
equally effective as the standard schedule. In addition, capecitabine has the advan-
tage of being able to be given on an outpatient basis.
Taken together, the original regimen of MMC and 5-FU remains the standard 
of care in CRT for SCCA, 45 years after its inception. There is a trend of using 
capecitabine instead of 5-FU because it is more patient friendly and equally effec-
tive. Arguably, MMC is more toxic than cisplatin in combination with 5-FU or 
capecitabine and RT [37], but this is dose dependent and seems to be equally effec-
tive in a single bolus of 10 mg/m2 as 12 or 15 mg/m2 or twice 10 mg/m2  
[9, 10, 25]. Furthermore, the combination of cisplatin and 5-FU is not more effec-
tive than MMC and 5-FU, but requires hospitalization for hydration procedures to 
prevent renal toxicity [26].
3. Prognostic factors in anal carcinoma
Well-known clinical prognostic factors in SCCA are age (>55 years better than 
≤55 years), sex (female better than male), tobacco smoking (worse), primary 
tumor size and site (anal margin better than anal canal), T- and N-stage, tumor 
ulceration (worse if present) and histological differentiation grade [32, 52, 53]. 
Other prognostic factors include HPV-HR and certain genetic alterations.
3.1 Human papillomavirus
HPV-HR is causally related with the onset and progression of SCCA [5]. Once 
integrated into the host DNA, the main viral oncoproteins E6 and E7 interact with 
the tumor suppressor proteins p53 and retinoblastoma protein (pRb), respectively. 
P53 has a key role in maintaining DNA integrity, whereas pRb is a negative regulator 
of the cyclin-dependent kinase inhibitor p16. Upon persistent HPV-HR infection, 
p53 becomes permanently inactivated, disrupting DNA repair processes, and pRb 
inactivation induces upregulation of p16. As such, p16 is sometimes used as a sur-
rogate marker of HPV-HR infection. These and other oncogenic processes lead to 
genomic instability, carcinogenesis and tumor progression. As a result, HPV-HR+ 
SCCA have a number of unique features, some of which have a prognostic or even a 
predictive value (Figure 2) [5].
Patients with HPV-HR+ SCCA have a significantly better outcome after CRT 
than HPV-HR-tumors [54–56]. Absolute difference in LRC/PFS varies from 
32 to 67%, whereas the difference in OS varies from 22 to 52%. Interestingly, 
within the HPV-HR+ tumors, LRC and OS after CRT are significantly better in 
patients with tumors carrying a high HPV-HR DNA load than in those with a 
low HPV-HR DNA load [57]. Intratumoral p16 expression is also correlated with 
LRC and PFS after CRT for SCCA [58]. An even stronger discriminating effect 
on LRC and PFS is observed by combining p16 expression and HPV DNA  
tumor load [57].
P53 and p16 expression/HPV-HR+ are inversely correlated in SCCA [56, 58]. 
In addition, p53 expression and disruptive TP53 mutations are associated with a 
significantly worse outcome after CRT [56, 58].
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3.2 Epidermal growth factor receptor
The epidermal growth factor receptor (EGFR) is frequently overexpressed in 
SCCA and this may confer a growth and survival advantage. In a subgroup analysis 
of the RTOG 98-11 trial, overexpression of EGFR and a downstream proliferation 
marker Ki67 was associated with a significantly worse DFS and OS [59]. In a recent 
small series of recurrent SCCA, high levels of alterations in the phosphoinositide 
3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) 
pathway, which is a growth and survival promoting pathway downstream of EGFR, 
were associated with poor OS [60].
3.3 Immune response
Persistent intratumoral HPV-HR infection can elicit a host immune response, 
which is mediated by immune checkpoint proteins such as cytotoxic T lymphocyte-
associated protein 4 (CTLA-4) and programmed cell death 1 (PD-1), expressed on 
activated T-cells and programmed cell death ligand 1 (PD-L1), expressed on tumors 
and various host cells [5, 61]. This can attract CD8+ T-lymphocytes into the tumor, 
Figure 2. 
Molecular features in HPV positive tumors [5]. Reproduced with permission of Elsevier.
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so-called tumor-infiltrating lymphocytes (TILs). HPV-mediated intratumoral 
immune response has a significant influence on LRC and DFS, as illustrated by the 
amount of CD8+ TILs and PD-1 and PD-L1 expression levels after CRT in SCCA 
(Figure 3) [62].
4. Biological agents
Although the standard regimen of CRT with MMC and 5-FU is effective in SCCA, 
there is still room for improvement, in particular in the locally advanced cases and 
tumors that carry poor prognostic factors. Attempts have been made to investigate 
newer, promising agents. Here we focus on two avenues that have been explored.
Cetuximab is a chimeric IgG1 monoclonal antibody with a high affinity for 
EGFR. It has been tested in a few phase II trials in combination with concurrent 
CRT in SSCA, and turned out to be very toxic and probably also less effective than 
the standard regimen [63–67].
Two phase II trials have been published on the use of anti-PD-1 monoclonal 
antibodies in recurrent and/or metastatic SCCA, that is nivolumab [68] and pem-
brolizumab [69]. Objective responses were observed in 24 and 17%, respectively, 
and stable disease in 42% of the latter [68, 69]. Adverse events were acceptable.
5. The role of surgery in anal carcinoma
5.1 Salvage abdominoperineal resection
Radical surgery for SCCA is restricted to locoregional recurrent, non-metas-
tasized and resectable tumors after CRT. The standard operation procedure is an 
abdominoperineal resection (APR), sometimes extended with resection of parts of 
the vagina or prostate, if involved, in order to obtain clear surgical margins [6]. This 
leaves a large pelvic floor defect, which preferably should be closed with a vertical 
Figure 3. 
Prognostic impact of CD8+/PD1 and DC8+/PD-L1 expression on LRC and DFS after CRT in SSCAC [62]. 
Reproduced with permission of Taylor and Francis.
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rectus abdominis myocutaneous flap (VRAM). Patients are left with a permanent 
colostomy. After APR, 5-year OS varies between 30 and 75%, depending upon 
whether or not clear resection margins have been obtained [6, 70]. Morbidity can be 
substantial, such as wound infections and poor healing of previously heavily irradi-
ated organs and tissues. Wide resections into non-irradiated tissues and reconstruc-
tions with plastic flap techniques reduce these serious complications [6].
5.2 Curative local excision
A particular role for curative surgery in first line treatment of SCCA is reserved 
for small, T1N0 tumors of the anal margin, suitable for local excision (LE). This 
is not a trivial decision to make and these patients deserve to be seen by an experi-
enced multidisciplinary team. Based on a recent pattern of care study in Australia, 
there is a wide variety in management of these small T1 tumors, depending upon 
the findings after a (non)excisional biopsy (Figure 4) [71]. In accordance with 
the guidelines and expert opinion, it is safe to say that T1N0 tumors < 1 cm, 
located in the anal margin, are good candidates for LE [34, 35]. This will probably 
account for only 4% of all anal cancers [72]. If pathological examination of the 
surgical specimen reveals that the resection is not radical, some form of additional 
treatment is warranted and should be discussed in a multidisciplinary team. If 
located in the anal canal, LE carries a risk of sphincter damage and is therefore 
relatively contraindicated. Nevertheless, a recent retrospective cohort study of 
Figure 4. 
Reported management of T1N0 anal cancer [71]. Reproduced with permission of Springer.
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the US National Cancer Database on 2243 cases with T1 N0 SCCA has shown that 
over the period 2004–2012 LE was increasingly used in the more recent years, also 
for tumors of the anal canal [73]. Although criticized for its lack of information 
on the exact tumor location, LRC and DFS [74, 75], this study and the Australian 
survey [71] illustrate that clinicians are reluctant to treat these small tumors with 
standard CRT.
6. Treatment strategy
Today’s clinical research on SCCA is focused on individualizing treatment as 
a function of estimated prognosis. A good example, for instance, is the UK trial 
“PersonaLising rAdioTherapy dOse in anal cancer” (PLATO), which offers a 
platform of 3 trials, ACT3, 4 and 5, for 3 different risk groups of SCCA [76].
ACT3 is a non-randomized trial for patients with low-risk T1N0 tumors of 
the anal margin, that undergo LE, followed by active surveillance if the resection 
margin is >1 mm. If the margin is ≤1 mm, postoperative reduced dose CRT is given 
locally (41.4 Gy in 23 fractions). In the Netherlands Cancer Institute, we use a 
somewhat different treatment policy for these tumors, taking a relatively new entity 
for SCCA into account, known as superficially invasive squamous cell carcinoma 
(SISCCA). SISCCA is defined as an invasive squamous cell carcinoma with an inva-
sive depth of ≤3 mm and a horizontal spread of ≤7 mm that has been completely 
excised [77]. In the cervix, SISCCA is known to bear a minimal risk of microscopic 
lymph node metastasis and it is assumed to be similar for SISCCA of the anus, 
although the data supporting this are scarce [77]. We therefore have adopted a close 
surveillance policy for SISCCA of the anal margin. If the resection margin is too 
close or involved, a wider excision is performed, if possible. If not, postoperative 
reduced dose RT alone is given to the anus (45 Gy in 25 fractions). For T1N0 tumors 
that are microscopically >3 mm in invasive depth or >7 mm in horizontal spread, 
we also irradiate the inguinal lymph nodes to 45 Gy in 25 fractions. We do not 
advocate CRT in these cases, because the results with RT alone are excellent [35, 78, 
79]. Furthermore, CRT is associated with an absolute increase of 9% of non-cancer 
related deaths compared with RT alone, mainly from cardiovascular cause and 
secondary tumors [44].
ACT4 is a randomized phase II trial for intermediate-risk tumors, T1–2 (≤4 cm) 
N0 or Nx, comparing LRC at 3 year after standard-dose CRT (50.4 Gy in 28 frac-
tions) versus a reduced-dose CRT (41.4 Gy in 23 fractions). In the French guidelines, 
the advice for T1 and small T2 tumors is to treat them with RT alone [35]. In the 
Netherlands Cancer Institute, we follow the Dutch National guidelines, which 
advocate RT alone for T1N0 tumors and CRT for all other stages [80].
ACT5 is a randomized seamless pilot/phase II/phase III trial for high-risk 
SCCA, T1-2N1-3 or T3-4Nany, comparing 3-years’ LRC after standard-dose CRT 
(53.2 Gy in 28 fractions) with that after 2 higher dose levels (58.8 and 61.2 Gy 
in 28 fractions) [76]. In the Netherlands Cancer Institute, we use CRT for these 
tumors with a relatively high radiation dose of 59.4 Gy in 30 fractions. We do 
not consider a lower radiation dose, because with VMAT the toxicity profile is 
acceptable [79].
7. Conclusions and future prospects
The treatment of SCCA has evolved over the last 5 decades from a mutilating 
radical surgical treatment with a modest survival probability to an individualized 
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radiation treatment with or without concurrent chemotherapy with good survival 
outcome and acceptable morbidity. Important improvements in radiation treatment 
techniques have been made, modern guidelines have been implemented and qual-
ity assurance is provided. However, there is still room for improvement. Quality of 
life analyses have infrequently been performed and are rarely taken into account in 
treatment decision making (e.g. [11, 81–83]). A good step forward in this respect is 
the development of a core outcome set of data, which should be the minimal infor-
mation required in future clinical trials for anal cancer [84]. Radiation dose de-esca-
lation and omitting concurrent chemotherapy for early tumors with good prognosis 
are important avenues to explore. On the other hand, new treatment modalities are 
needed for poor prognostic cases, such as HPV-HR negative SCCA. Immunotherapy 
seems to be a promising modality, either alone [68, 69] or in combination with 
chemotherapy [85]. Exploring the molecular profile of SCCA may reveal new 
potentially therapeutic targets and prognostic and predictive markers [60, 86, 87]. 
Circulating tumor DNA at baseline and in follow-up may become an important tool 
in treatment decision making [88]. These new insights and therapeutic avenues may 
eventually change the landscape of anal cancer treatment in the near future.
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Nomenclature
clinical target 
volume (CTV)  
the microscopic tumor volume, based upon the estimated   
 microscopic lymphatic tumor spread
CTLA-4  a member of the immunoglobulin superfamily, expressed   
 on the cell surface of activated T-cells. It binds to B7-1 and   
 B7-2 molecules of antigen presenting cells, which down-  
 regulates the immune response, a process     
 frequently occurring in cancer
3D-conformal 
radiotherapy (3D-CRT) 
a 3-dimensional radiation treatment technique, which   
 allows to shape the radiation dose distribution  
 “conformal” to the shape of the planning target volume
epidermal growth 
factor receptor (EGFR) 
a transmembrane protein, which is frequently  
 overexpressed in a number of cancers. When activated,   
 either by ligand binding (normal) or mutations    
 (abnormal), it stimulates downstream signaling pathways,  
 which promote DNA synthesis, cell growth and cell migration
gross tumor 
volume (GTV)  
the macroscopic tumor volume as visualized with CT, MRI  
and/or PET
intensity-modulated 
radiotherapy (IMRT) 
a refined version of 3D-conformal radiotherapy, where   
 various segments within a radiation field allow to modulate   
 the radiation fluency, in order to obtain conformity    
 to irregularly shaped volumes
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P16  a tumor suppressor protein, which slows down the cell   
 cycle by inhibiting cyclin-dependent kinases
P53  a tumor suppressor protein, that plays an essential role in   
 maintaining DNA integrity by various mechanisms. It can   
 activate DNA repair proteins and induce cell cycle arrest to  
 allow DNA repair, or, alternatively, initiate programmed   
 cell death if DNA damage appears to be irreparable
PD-1  a member of the immunoglobulin superfamily, expressed   
 on T-cells and pro-B-cells. It binds to PD-L1 on macro phages  
 and dendritic cells, which down-regulates the immune   
 system and promotes self-tolerance, a protective    
 mechanism against auto-immune disease. PD-L1 is  
 frequently overexpressed in many tumors, which promotes  
 tumor tolerance
PI3K/AKT/mTOR 
pathway  
an intracellular signaling pathway involved in cell cycle   
regulation. It is frequently overactive in many cancers,   
 eliciting a growth and survival advantage
planning target 
volume (PTV)  
the extension of CTV needed to account for systematic   
and random set up variation of the patient positioning
retinoblastoma 
protein (pRb)  
a tumor suppressor protein, which prevents excessive cell   
growth by inhibiting DNA synthesis
volumetric modulated 
arc therapy (VMAT) 
a refined version of IMRT, in which the radiation dose is   
 delivered by rotating the gantry around the patient. The   
 collimator head also rotates and contains moving leaves.  
 The dose rate is also variable
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